SOUTH SAN FRANCISCO, Calif., April 1, 2013 (GLOBE NEWSWIRE) -- Talon Therapeutics, Inc., (OTCQB:TLON), today reported financial results for the fourth quarter and year ended December 31, 2012.
2012 Corporate Highlights
FDA accelerated approval of Marqibo® for the treatment of Philadelphia chromosome negative adult acute lymphoblastic leukemia (ALL) patients in second or greater relapse or whose disease has progressed following two or more prior lines of anti-leukemia therapy.
Enrollment and dosing of the first patient in the Phase 3 confirmatory study of Marqibo®, named HALLMARQ, in adult patients with newly diagnosed Philadelphia chromosome negative ALL.
Publication of the Marqibo® RALLY Study in the Journal of Clinical Oncology (JCO).
